RxDoctor Payments DataLook up a doctor →

Daniel Groisser, MD

Dermatology · Verona, NJNPI 1376514745

Payments from drug & device makers

$70,593in general payments, 2019–2025

Across 1,535 payments — averaging $45.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Journey Medical Corporation$11K
  • Pfizer$9K
  • AbbVie$7K
  • E.r. Squibb & Sons, L.L.C.$6K
  • Sun Pharmaceutical Industries Inc.$6K
  • Novartis$6K
  • plus $26K from 40 others

What the payments were for

  • Consulting fees$35,81051%
  • Speaking & faculty fees$10,42015%
  • Travel & lodging$2,8854%
  • Food & beverage$21,05630%
  • Education$4231%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$70,593 in reported general payments places this provider in the 90th percentile of 394 dermatology providers in New Jersey.

See all dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$513,967
Medicare patients
718
Services billed
7,040

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab27$203,778
Dupixent PenDupilumab47$178,206
TremfyaGuselkumab11$151,411
OtezlaApremilast26$121,053
OpzeluraRuxolitinib Phosphate17$35,076
Fluocinonide218$9,683
Acitretin14$8,003
Triamcinolone Acetonide351$5,808
Halobetasol Propionate122$5,764
Fluocinolone Acetonide111$5,697
Mupirocin738$5,404
Clobetasol Propionate96$3,954
Clindamycin Phosphate85$3,652
CiclopiroxCiclopirox Olamine121$2,843
Metronidazole25$2,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$3,697$151,41111 claims
AmgenOtezla$237$121,05326 claims
Incyte CorporationOpzelura$1,098$35,07617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 394 dermatology providers in New Jersey.

Other dermatology in Verona

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →